Table of Content


List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
5-Hydroxytryptamine Receptor 7 (5 HT7 or 5 HTX or Serotonin Receptor 7 or HTR7) - Overview
5-Hydroxytryptamine Receptor 7 (5 HT7 or 5 HTX or Serotonin Receptor 7 or HTR7) - Therapeutics Development
Products under Development by Stage of Development
Products under Development by Therapy Area
Products under Development by Indication
Products under Development by Companies
Products under Development by Universities/Institutes
5-Hydroxytryptamine Receptor 7 (5 HT7 or 5 HTX or Serotonin Receptor 7 or HTR7) - Therapeutics Assessment
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
5-Hydroxytryptamine Receptor 7 (5 HT7 or 5 HTX or Serotonin Receptor 7 or HTR7) - Companies Involved in Therapeutics Development
Adamed Pharma SA
Avineuro Pharmaceuticals Inc
Celon Pharma SA
Core One Labs Inc
Daya Drug Discoveries Inc
H. Lundbeck AS
Johnson & Johnson
LB Pharmaceuticals Inc
Praeventix LLC
Reviva Pharmaceuticals Inc
Sumitomo Pharma Co Ltd
Sunovion Pharmaceuticals Inc
5-Hydroxytryptamine Receptor 7 (5 HT7 or 5 HTX or Serotonin Receptor 7 or HTR7) - Drug Profiles
5HT7 Agonist - Drug Profile
Product Description
Mechanism Of Action
ADN-1184 - Drug Profile
Product Description
Mechanism Of Action
ADN-3662 - Drug Profile
Product Description
Mechanism Of Action
amisulpride - Drug Profile
Product Description
Mechanism Of Action
History of Events
AVN-101 - Drug Profile
Product Description
Mechanism Of Action
History of Events
brilaroxazine - Drug Profile
Product Description
Mechanism Of Action
History of Events
DDD-028 - Drug Profile
Product Description
Mechanism Of Action
dimethyltryptamine - Drug Profile
Product Description
Mechanism Of Action
JNJ-18038683 - Drug Profile
Product Description
Mechanism Of Action
LB-102 - Drug Profile
Product Description
Mechanism Of Action
History of Events
LB-102 LA - Drug Profile
Product Description
Mechanism Of Action
LB-104 - Drug Profile
Product Description
Mechanism Of Action
lurasidone hydrochloride - Drug Profile
Product Description
Mechanism Of Action
History of Events
Small Molecules to Antagonize 5 HT7 Receptors for Crohn’s Disease and Ulcerative Colitis - Drug Profile
Product Description
Mechanism Of Action
History of Events
Small Molecules to Target 5-HT7R for Sleep Disorders - Drug Profile
Product Description
Mechanism Of Action
vortioxetine hydrobromide - Drug Profile
Product Description
Mechanism Of Action
History of Events
5-Hydroxytryptamine Receptor 7 (5 HT7 or 5 HTX or Serotonin Receptor 7 or HTR7) - Dormant Products
5-Hydroxytryptamine Receptor 7 (5 HT7 or 5 HTX or Serotonin Receptor 7 or HTR7) - Discontinued Products
5-Hydroxytryptamine Receptor 7 (5 HT7 or 5 HTX or Serotonin Receptor 7 or HTR7) - Product Development Milestones
Featured News & Press Releases
May 03, 2022: Reviva Pharmaceuticals announces update on RECOVER, a pivotal phase 3 global study evaluating brilaroxazine for the treatment of schizophrenia
Apr 26, 2022: Reviva Pharmaceuticals to host key opinion leader webir on brilaroxazine for schizophrenia and Other neuropsychiatric disorders
Apr 11, 2022: Vortioxetine demonstrates advantage on daily and social functioning vs. desvenlafaxine in a large head-to-head study
Mar 03, 2022: Core One Labs announces successful proof-of-concept for biosynthetic N-methyltryptamine (NMT)
Feb 10, 2022: Core One Labs expects imminent breakthrough to produce NMT, Precursor to DMT
Feb 09, 2022: Sunovion and Otsuka initiate Phase 3 clinical development of non-racemic amisulpride for the treatment of people with bipolar depression
Feb 01, 2022: Reviva Pharmaceuticals announces first patients dosed in pivotal phase 3 study and long-term safety trial evaluating Brilaroxazine for the treatment of schizophrenia
Jan 10, 2022: Reviva Pharmaceuticals Holdings receives FDA may proceed letter for pivotal phase 3 clinical trial and long-term safety trial evaluating Brilaroxazine for the treatment of Schizophrenia
Dec 07, 2021: LB announces presentation of full results of dopamine receptor occupancy study of LB-102 at the 2021 ACNP conference
Oct 04, 2021: LB Pharmaceuticals presents results of dopamine receptor occupancy studies of LB-102 at ECNP conference
Oct 01, 2021: U.S. court issues decision in Trintellix patent litigation upholding active ingredient patent
May 03, 2021: H. Lundbeck: New study finds that vortioxetine helps patients with MDD and comorbid Generalized Anxiety Disorder
May 03, 2021: Sunovion presents data from marketed and late-stage development psychiatric compounds at the American Psychiatric Association (APA) Annual Meeting 2021
Apr 26, 2021: Reviva announces full details of positive phase 2 clinical trial results for acute Schizophrenia
Apr 22, 2021: Vortioxetine significantly improves overall functioning in a global real-world study in Major Depressive Disorder
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer



List of Figures

List of Figures
Number of Products under Development by Stage of Development, 2022
Number of Products under Development by Therapy Areas, 2022
Number of Products under Development by Top 10 Indications, 2022
Number of Products by Mechanism of Actions, 2022
Number of Products by Stage and Mechanism of Actions, 2022
Number of Products by Routes of Administration, 2022
Number of Products by Stage and Routes of Administration, 2022
Number of Products by Stage and Molecule Type, 2022

List of Tables

List of Tables
Number of Products under Development by Stage of Development, 2022
Number of Products under Development by Therapy Areas, 2022
Number of Products under Development by Indications, 2022
Number of Products under Development by Companies, 2022
Products under Development by Companies, 2022
Products under Development by Companies, 2022 (Contd..1)
Products under Development by Companies, 2022 (Contd..2)
Number of Products under Investigation by Universities/Institutes, 2022
Products under Investigation by Universities/Institutes, 2022
Number of Products by Stage and Mechanism of Actions, 2022
Number of Products by Stage and Route of Administration, 2022
Number of Products by Stage and Molecule Type, 2022
Pipeline by Adamed Pharma SA, 2022
Pipeline by Avineuro Pharmaceuticals Inc, 2022
Pipeline by Celon Pharma SA, 2022
Pipeline by Core One Labs Inc, 2022
Pipeline by Daya Drug Discoveries Inc, 2022
Pipeline by H. Lundbeck AS, 2022
Pipeline by Johnson & Johnson, 2022
Pipeline by LB Pharmaceuticals Inc, 2022
Pipeline by Praeventix LLC, 2022
Pipeline by Reviva Pharmaceuticals Inc, 2022
Pipeline by Sumitomo Pharma Co Ltd, 2022
Pipeline by Sunovion Pharmaceuticals Inc, 2022
Dormant Products, 2022
Dormant Products, 2022 (Contd..1)
Discontinued Products, 2022